CDMA announces executive appointments
NOVI, Mich. — Chain Drug Marketing Association has named a VP finance and store brands, as well as a new director of business development.
John Devine, who will serve as VP finance and store brands, has been involved with projects and programs at CDMA for the past 15 years. In his new role, he will be responsible for increasing and enhancing the success of CDMA’s store brand program. Devine will report to CDMA president Jim Devine.
Annmarie Zaremba, who will serve as director of business development, will be responsible for the development and growth of CDMA’s supplier, retailer and wholesale membership by working with CDMA VP sales Judy Aspinall and the organization’s category managers. Zaremba also plans locate, define and secure business relationships, CDMA said.
FDA approves generic cardiovascular drug
MORRISTOWN, N.J. — The Food and Drug Administration has approved a generic drug for treating blood pressure and chest pain.
Actavis announced Wednesday the approval of diltiazem hydrochloride extended-release capsules.
The drug is a generic version of Valeant’s Tiazac. The branded drug and its generic equivalents had sales of about $76.3 million in 2011, according to IMS Health.
GPhA appoints CVS Caremark public policy director
WASHINGTON — An executive from CVS Caremark will guide policy for a generic drug industry trade association.
The Generic Pharmaceutical Association said Wednesday that it had appointed CVS Caremark senior director of public policy Christine Simmon to run its policy shop as SVP policy and strategic alliances, effective Oct. 24. Christine Simmon previously worked for the GPhA as VP policy, public affairs and development from 2002 to 2006.
"We are delighted to welcome Christine back to our professional team," GPhA president and CEO Ralph Neas said. "Her vast experience working with legislators, regulatory agencies and industry leaders on key healthcare issues will serve our industry well. She will play a leading role in our mission to show that safe, effective and affordable generic medicines are a critical part of the solution to controlling costs and lowering the nation’s healthcare bill."
Simmon also will help expand the GPhA’s partnerships with other industry, consumer and public policy organizations, the group said.